Personal care company The Honest Company (NASDAQ:HNST) announced better-than-expected revenue in Q4 CY2024, with sales up 10.6% year on year to $99.84 million. Its GAAP loss of $0.01 per share was in line with analysts’ consensus estimates.
Agricultural and farm machinery company Titan (NSYE:TWI) missed Wall Street’s revenue expectations in Q4 CY2024, with sales falling 1.7% year on year to $383.6 million. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $475 million at the midpoint, or 1.9% above analysts’ estimates. Its GAAP profit of $2 per share was significantly above analysts’ consensus estimates.
The Asia-Pacific economic and corporate calendar is virtually empty on Thursday, allowing investors to take their cue from global drivers, two of which stand out above all others - Nvidia's earnings and U.S. President Donald Trump's latest musings on tariffs. Nvidia reported fourth-quarter earnings after the market close on Wednesday. Revenue grew 78% to $39.3 billion, beating estimates of $38.04 billion, and the firm's forecast for first-quarter revenue was also above market estimates.
Plant-based protein company Beyond Meat (NASDAQ:BYND) announced better-than-expected revenue in Q4 CY2024, with sales up 4% year on year to $76.66 million. On the other hand, the company’s full-year revenue guidance of $327.5 million at the midpoint came in 1.3% below analysts’ estimates. Its non-GAAP loss of $0.65 per share was 44.3% below analysts’ consensus estimates.
Water management company Northwest Pipe (NASDAQ:NWPX) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 8.6% year on year to $119.6 million. Its GAAP profit of $1 per share was 9.5% above analysts’ consensus estimates.
Healthcare software provider Health Catalyst (NASDAQ:HCAT) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 6% year on year to $79.61 million. On the other hand, next quarter’s revenue guidance of $79 million was less impressive, coming in 3.5% below analysts’ estimates. Its non-GAAP profit of $0.04 per share was 47.6% below analysts’ consensus estimates.
Salesforce's outlook fell short of analysts’ expectations, sending shares lower in extended trading Wednesday.
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the market’s revenue expectations in Q4 CY2024, but sales rose 34.3% year on year to $181.9 million. On the other hand, the company’s full-year revenue guidance of $925 million at the midpoint came in 8.2% above analysts’ estimates. Its GAAP profit of $0.26 per share was 39% below analysts’ consensus estimates.
Leading edge card issuer Marqeta (NASDAQ: MQ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 14.3% year on year to $135.8 million. Guidance for next quarter’s revenue was better than expected at $135.7 million at the midpoint, 1.7% above analysts’ estimates. Its GAAP loss of $0.05 per share was in line with analysts’ consensus estimates.
Energy recovery device manufacturer Energy Recovery (NASDAQ:ERII) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 17.3% year on year to $67.08 million. Its non-GAAP profit of $0.50 per share was 24% above analysts’ consensus estimates.